Casual Observer

[Casual Observer @IvoryTowerCBpwr]

Reminder that $DNA short report about related party transactions fraud was disproven last earnings report. It does not rely on related parties to grow Foundry Revenue.

[Casual Observer @IvoryTowerCBpwr]

@LeonSimons8 Are you actually surprised though? You did a presentation in ‘21 on the major contributor to last year’s temperature anomaly (sulphate aerosols).

Maybe we should have considered the trade-off before regulating those emissions

https://t.co/wWXNzLppyn

[Casual Observer @IvoryTowerCBpwr]

@trengriffin Seems like they're going to face saturation issues unless they increase the satellite density. Already seeing speeds slow dramatically during peak hours in coastal Virginia. Getting bad enough that I'm paying $40k for Cox Cable to run a half-mile line to my house & cabin

[Casual Observer @IvoryTowerCBpwr]

@jrkelly @SynBio1 Jake kills it as a spokesperson for synbio. You guys have built a great team — everyone seems suited to their niche. Ryan doing amazing work on the partnership side, AMW great all around and I think will excel in the new role. And ofc the eng/scientists tackling 100+ programs 🫡

[Casual Observer @IvoryTowerCBpwr]

@hmeisler @Morgan_03 @Morgan_03

[Casual Observer @IvoryTowerCBpwr]

@davidbelle_ She has a twitter and has been posting about this for months. Blows my mind that this is the first people are hearing about it -- never really made the mainstream news.

[Casual Observer @IvoryTowerCBpwr]

@melindiscott @davidbelle_ These things can’t be explained you just have to watch the early seasons

[Casual Observer @IvoryTowerCBpwr]

@melindiscott @davidbelle_ Haven’t seen this show in years but the OG seasons where you know they needed the $1000/episode episode fee and there was no potential fame involved was great. Actual reality TV, completely predatory like that love on the spectrum show (yes I’m a terrible person)

[Casual Observer @IvoryTowerCBpwr]

@melindiscott @davidbelle_ Nah I’m with David you watch these with the lady to make sure she knows how low the bar actually goes. Nothing brings perspective like seeing some guy mooch a firehouse apartment off of a friend while his wife dies inside. And no neck Ed? That’s cinema

[Casual Observer @IvoryTowerCBpwr]

Finally working out and all it took was every shitco getting squeezed

[Casual Observer @IvoryTowerCBpwr]

Bought some $BEAM, in at around $22.10

[Casual Observer @IvoryTowerCBpwr]

I get the feeling the inflation reduction act will push more money into the RNAi/gene editing/CAR-T/anything but small molecule space. Narrative hasn’t shifted yet but the small molecule patent cliff is real

[Casual Observer @IvoryTowerCBpwr]

@MJD007 Just my 2c, may be completely off. It would engineer good YoY comps though and likely induce buying and extend the runway

[Casual Observer @IvoryTowerCBpwr]

Thoughts on $DNA earnings:

Terrible, obviously. I’ve said before that I expected Ginkgo to push downstream revenue recognition & programs into 2024 to manufacture a better revenue curve, but $4m recognition in downstream revenues this year is… exceptionally low.

[Casual Observer @IvoryTowerCBpwr]

@MJD007 improves. Hope these two things send share prices higher so you can do a raise in ‘24 or ‘25 and extend the runway further until bio funding picks up again

[Casual Observer @IvoryTowerCBpwr]

Also I suppose prioritizing the early-mid stages of these projects isn’t “financial engineering,” but it certainly seems like a business decision meant to show more YoY revenue growth in the future. What the co really needs is a better biotech funding environment

[Casual Observer @IvoryTowerCBpwr]

Their updates on program completion & associated graphic in the ER slides seems to corroborate the idea that they’re focused on moving projects forward but not obsessed with completions/commercialization. Leaves a lot of final legs to be completed in ‘24 to show revs/completions

[Casual Observer @IvoryTowerCBpwr]

Correction: meant $4m downstream revenue in Q3 2023